Table 4. HS Serotypes with Proportional Estimates of 2% or Greater by Economic Development Status.
| % | lci | uci | |
| Developed (n = 1,222) | |||
| HS4c | 17.5 | 15.2 | 19.8 |
| HS2 | 16.5 | 13.8 | 19.1 |
| HS1/44 | 9.0 | 7.8 | 10.1 |
| HS11 | 3.5 | 2.4 | 4.5 |
| HS6/7 | 2.9 | 2.1 | 3.6 |
| HS8/17 | 2.8 | 2.1 | 3.4 |
| HS5/31 | 2.6 | 2.0 | 3.3 |
| HS3 | 2.1 | 1.6 | 2.6 |
| Developing (n = 20,172) | |||
| HS4c | 8.2 | 4.8 | 11.5 |
| HS1/44 | 5.0 | 2.9 | 7.1 |
| HS2 | 5.0 | 2.8 | 7.3 |
| HS5/31 | 4.3 | 2.3 | 6.3 |
| HS3 | 3.7 | 1.7 | 5.7 |
| HS8/17 | 3.5 | 1.5 | 5.5 |
| HS23/36 | 3.3 | 1.5 | 5.1 |
| HS15 | 2.9 | 1.1 | 4.6 |
| HS53 | 2.9 | 1.0 | 4.8 |
Tables 2–4: HS serotypes with a proportional representation of 2% or greater, Globally (Table 2), by Region (Table 3), and by Economic Status (Table 4). Proportional estimates (%) were computed using the DerSimonian & Laird random effects model and include the upper (uci) and lower (lci) 95% confidence intervals. Note: Isolates categorized as a cross-reactive pair HS serotype (e.g. HS1/44, HS5/31, HS6/7, HS8/17, and HS23/36) were originally reported as one of the two serotypes or as the paired serotype itself. Isolates categorized as HS4 complex (or HS4c) represent isolates reported as any combination of the following serotypes HS 4/13/16/43/50/63/64/65.